JP2007532496A5 - - Google Patents

Download PDF

Info

Publication number
JP2007532496A5
JP2007532496A5 JP2007506660A JP2007506660A JP2007532496A5 JP 2007532496 A5 JP2007532496 A5 JP 2007532496A5 JP 2007506660 A JP2007506660 A JP 2007506660A JP 2007506660 A JP2007506660 A JP 2007506660A JP 2007532496 A5 JP2007532496 A5 JP 2007532496A5
Authority
JP
Japan
Prior art keywords
solid
reaction
esters
mmol
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007506660A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007532496A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2005/000244 external-priority patent/WO2005097107A2/en
Publication of JP2007532496A publication Critical patent/JP2007532496A/ja
Publication of JP2007532496A5 publication Critical patent/JP2007532496A5/ja
Pending legal-status Critical Current

Links

JP2007506660A 2004-04-08 2005-04-08 ジフェニルオキソ−インドール−2−オン化合物および癌の処置におけるそれらの使用 Pending JP2007532496A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200400576 2004-04-08
DKPA200400693 2004-05-01
DKPA200401153 2004-07-27
DKPA200401216 2004-08-11
PCT/DK2005/000244 WO2005097107A2 (en) 2004-04-08 2005-04-08 Diphenyl - indol-2-on compounds and their use in the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2007532496A JP2007532496A (ja) 2007-11-15
JP2007532496A5 true JP2007532496A5 (cg-RX-API-DMAC7.html) 2008-05-22

Family

ID=34965522

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007506660A Pending JP2007532496A (ja) 2004-04-08 2005-04-08 ジフェニルオキソ−インドール−2−オン化合物および癌の処置におけるそれらの使用

Country Status (15)

Country Link
US (1) US20070299102A1 (cg-RX-API-DMAC7.html)
EP (1) EP1734951A2 (cg-RX-API-DMAC7.html)
JP (1) JP2007532496A (cg-RX-API-DMAC7.html)
KR (1) KR20060130781A (cg-RX-API-DMAC7.html)
CN (1) CN1953747A (cg-RX-API-DMAC7.html)
AU (1) AU2005230232A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0509745A (cg-RX-API-DMAC7.html)
CA (1) CA2562399A1 (cg-RX-API-DMAC7.html)
CR (1) CR8673A (cg-RX-API-DMAC7.html)
EA (1) EA013209B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP066913A (cg-RX-API-DMAC7.html)
IL (1) IL178012A0 (cg-RX-API-DMAC7.html)
NO (1) NO20065034L (cg-RX-API-DMAC7.html)
NZ (1) NZ550222A (cg-RX-API-DMAC7.html)
WO (1) WO2005097107A2 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2555812A1 (en) 2004-02-13 2005-09-01 President And Fellows Of Harvard College 3-3-di-substituted-oxindoles as inhibitors of translation initiation
MY144968A (en) * 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR053710A1 (es) * 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
AR053713A1 (es) * 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
CA2626456C (en) 2005-10-18 2018-01-09 George Mason Intellectual Properties, Inc. Mtor pathway theranostic
BRPI0719166A2 (pt) * 2006-10-12 2014-06-03 Xenon Pharmaceuticals Inc Derivados de espiro-oxindol tricíclicos e seus usos como agentes terapêuticos
WO2008046049A1 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
EP2073806B1 (en) * 2006-10-12 2012-02-15 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
EP2102158A1 (en) * 2006-12-11 2009-09-23 Topo Target A/S Prodrugs of diphenyl ox- indol- 2 -one compounds for the treatment of cancers
CA2684552A1 (en) * 2007-04-24 2008-10-30 Topotarget A/S Substituted 3-(4-hydroxyphenyl)-indolin-2-one compounds
CN102015705B (zh) 2008-02-26 2013-11-13 武田药品工业株式会社 稠合的杂环衍生物及其用途
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
WO2010045197A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
HRP20150882T1 (hr) 2008-10-17 2015-09-25 Xenon Pharmaceuticals Inc. Spirooksindolski spojevi i njihova upotreba kao terapijska sredstva
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
EP2393827B1 (en) 2009-02-05 2015-10-07 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
WO2010109008A1 (en) 2009-03-26 2010-09-30 Topotarget A/S Prodrugs of substituted 3-(4-hydroxyphenyl)-indolin-2-ones
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
US20110086899A1 (en) * 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
PE20170202A1 (es) 2009-10-14 2017-03-24 Xenon Pharmaceuticals Inc Metodos sinteticos para compuestos espiro-oxoindol
BR112012009262A2 (pt) * 2009-10-23 2019-09-24 Health Research Inc ''método para inibir a proliferação de células de câncer positivo para ar em um indivíduo diagnosticado com,ou qual se suspeita que tenha cânce positivo para ar e método para identificar se um indivíduo é um candidato para tratamento com uma composiçâo
RU2596488C2 (ru) 2010-02-26 2016-09-10 Ксенон Фармасьютикалз Инк. Фармацевтические композиции спиро-оксиндольного соединения для местного введения и их применение в качестве терапевтических агентов
AU2014207272A1 (en) * 2013-01-18 2015-07-30 Neal D. Andruska Estrogen receptor inhibitors
CA2904170A1 (en) 2013-03-14 2014-09-25 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
KR20160058774A (ko) 2013-08-12 2016-05-25 토카이 파마슈티컬, 아이엔씨. 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
US10428331B2 (en) 2014-01-16 2019-10-01 Musc Foundation For Research Development Targeted nanocarriers for the administration of immunosuppressive agents
AR103636A1 (es) 2015-02-05 2017-05-24 Teva Pharmaceuticals Int Gmbh Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
US20210220329A1 (en) * 2018-02-08 2021-07-22 The United State of America, as represented by the Secretary, Department of Health and Human Service A method of treating triple-negative breast cancer
EP3817741A4 (en) 2018-07-03 2022-07-06 The Board of Trustees of the University of Illinois ACTIVATORS OF THE UNFOLDING PROTEIN RESPONSE
EP3912625A1 (en) * 2020-05-20 2021-11-24 Kaerus Bioscience Limited Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders
CN114213396B (zh) * 2022-01-27 2023-03-24 深圳市乐土生物医药有限公司 一种吲哚-2-酮类化合物及其制备方法与用途
CN119019312B (zh) * 2024-10-24 2025-01-28 苏州宜联生物医药有限公司 一种吲哚-2-酮衍生物、其抗体药物偶联物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2258505A1 (de) * 1971-12-02 1973-06-07 Ciba Geigy Ag Oxindoldiamine und verfahren zu ihrer herstellung
ES426436A1 (es) * 1974-05-18 1976-07-01 Andreu Sa Dr Procedimiento para la obtencion de derivados de la 3,3-bis (4-hidroxifenil)-2-indolinona.
JPS5590943A (en) * 1978-12-28 1980-07-10 Fuji Photo Film Co Ltd Photosensitive material and image forming method applicable thereto
DE3510730A1 (de) * 1985-03-08 1986-09-11 Möve-Werk GmbH & Co KG, 7410 Reutlingen Verfahren zur herstellung eines baumwollgewebes
ATE259222T1 (de) * 1997-11-20 2004-02-15 Harvard College Substituierte diphenylindanone, -indane und - indolverbindungen und deren analogue zur verwendung in der prophylaxe und behandlung von krankheiten die sich durch anormale zellproliferation auszeichnen
US6800658B2 (en) * 1997-11-20 2004-10-05 Children's Medical Center Corporation Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment of prevention of diseases characterized by abnormal cell proliferation
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
JP2006508893A (ja) * 2002-03-15 2006-03-16 イーライ・リリー・アンド・カンパニー ステロイドホルモン核内レセプターモジュレーターとしてのジヒドロインドール−2−オン誘導体
CA2555812A1 (en) * 2004-02-13 2005-09-01 President And Fellows Of Harvard College 3-3-di-substituted-oxindoles as inhibitors of translation initiation

Similar Documents

Publication Publication Date Title
JP2019510128A (ja) スガマデクスの調製のための改善されたプロセス
JP2011503053A (ja) 2‐ヒドロキシ‐5‐フェニルアルキルアミノ安息香酸誘導体及びその塩の製造方法
JP2002513003A5 (cg-RX-API-DMAC7.html)
WO2019137358A1 (zh) 一种parp抑制剂及其中间体的制备方法
CN1108029A (zh) 克拉维酸的二胺盐
WO2010083722A1 (zh) 一锅煮方法合成corey内酯的工艺
CN100349884C (zh) 3-苯基呋喃-2-酮衍生物作为环加氧酶的抑制剂
JP2010043053A (ja) 高純度のレバミピドの製造方法
JP4433365B2 (ja) 4−(2−メチル−1−イミダゾリル)−2,2−ジフェニルブタンアミドの製造方法
CA2792473A1 (en) A process for the preparation of highly pure ambrisentan
CN111909067A (zh) 一种d-青霉胺的有机全合成方法
US6861525B2 (en) Process for the preparation imidazo[1,2-A]pyridine-3-acetamides
DE60108112D1 (de) Verfahren zur herstellung von carbostyril-derivaten
CN112812101A (zh) 一种阿伐那非杂质的制备方法
JP5087059B2 (ja) 4−(2−メチル−1−イミダゾリル)−2,2−ジフェニルブタンアミドの製造方法
CN111978264B (zh) 一种地拉罗司的工业化生产方法
AU604583B2 (en) Process for the preparation of a benzoic acid ester
JP3899626B2 (ja) 2−メルカプトチアゾ−ルの製法
JP4675234B2 (ja) 光学活性なキノロンカルボン酸誘導体の製造中間体およびその製造法
JP4500160B2 (ja) アミドフェノールの製造法
CN107674023A (zh) 一种瑞巴派特的合成方法
EP0435995A1 (en) New quinoline derivatives and process for the preparation thereof
JP3983979B2 (ja) 3−(ヒドロキシメチル)クロメン−4−オン類およびその製造方法
CN100491340C (zh) 一种制备2-{4-[[(3,5-二甲基苯胺)羰基]甲基]苯氧基}-2-甲基丙酸钠的方法
JPH03279343A (ja) 環状ケトン類の製造方法